Tryp Therapeutics Inc. (TRYPF)
Chart Events
Performance Outlook
| Previous Close | 0.2044 |
| Open | 0.2040 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.1911 - 0.2121 |
| 52 Week Range | 0.1530 - 1.0400 |
| Volume | |
| Avg. Volume | 73,566 |
| Market Cap | 13.534M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Tryp Therapeutics to Participate in Healthcare Conferences in January 2022
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it will present next week at the H.C. Wainwright Bioconnect Conference and the Biotech Showcase.
- PR Newswire
Tryp Therapeutics Announces Advancement of Phase 2a Clinical Trial in Binge Eating Disorder
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the receipt of correspondence from the U.S. Food and Drug Administration (FDA) affirming the Company's ability to proceed with a Phase 2a clinical trial evaluating the use of synthetic psilocybin for binge eating disorder.
- PR Newswire
Tryp Therapeutics Receives Confirmation from FDA to Proceed with Phase 2a Study in Fibromyalgia
Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has received confirmation from the U.S. Food and Drug Administration ("FDA") that its review of Tryp's Investigational New Drug ("IND") application is complete and that the Company may proceed with its clinical study in fibromyalgia.
